Orchard Therapeutics plc [NASDAQ: ORTX] price surged by 12.52 percent to reach at $0.78. The company report on January 14, 2021 that Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD).
Interactions with FDA anticipated by mid-2021 to determine the BLA filing strategy for OTL-200.
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OTL-200, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of early-onset metachromatic leukodystrophy (MLD). In late 2020, the FDA cleared the company’s Investigational New Drug (IND) application for OTL-200, and the therapy also recently was approved in the European Union (EU) under the brand name, LibmeldyTM.
A sum of 2967415 shares traded at recent session while its average daily volume was at 1.42M shares. Orchard Therapeutics plc shares reached a high of $7.09 and dropped to a low of $6.10 until finishing in the latest session at $7.01.
Guru’s Opinion on Orchard Therapeutics plc [ORTX]:
Cantor Fitzgerald have made an estimate for Orchard Therapeutics plc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 07, 2021. The new note on the price target was released on June 01, 2020, representing the official price target for Orchard Therapeutics plc stock. Previously, the target price had yet another raise to $31, while Guggenheim analysts kept a Buy rating on ORTX stock.
The Average True Range (ATR) for Orchard Therapeutics plc is set at 0.64, with the Price to Sales ratio for ORTX stock in the period of the last 12 months amounting to 203.40. The Price to Book ratio for the last quarter was 3.37, with the Price to Cash per share for the same quarter was set at 2.17.
ORTX Stock Performance Analysis:
Orchard Therapeutics plc [ORTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.94. With this latest performance, ORTX shares gained by 54.07% in over the last four-week period, additionally plugging by 29.57% over the last 6 months – not to mention a drop of -54.51% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORTX stock in for the last two-week period is set at 68.81, with the RSI for the last a single of trading hit 70.72, and the three-weeks RSI is set at 66.49 for Orchard Therapeutics plc [ORTX]. The present Moving Average for the last 50 days of trading for this stock 4.88, while it was recorded at 6.70 for the last single week of trading, and 6.25 for the last 200 days.
Insight into Orchard Therapeutics plc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Orchard Therapeutics plc [ORTX] shares currently have an operating margin of -7578.07 and a Gross Margin at +1.31. Orchard Therapeutics plc’s Net Margin is presently recorded at -6503.06.
Return on Total Capital for ORTX is now -58.26, given the latest momentum, and Return on Invested Capital for the company is -50.45. Return on Equity for this stock declined to -53.76, with Return on Assets sitting at -42.88. When it comes to the capital structure of this company, Orchard Therapeutics plc [ORTX] has a Total Debt to Total Equity ratio set at 15.34. Additionally, ORTX Total Debt to Total Capital is recorded at 13.30, with Total Debt to Total Assets ending up at 11.50. Long-Term Debt to Equity for the company is recorded at 13.38, with the Long-Term Debt to Total Capital now at 11.60.
Reflecting on the efficiency of the workforce at the company, Orchard Therapeutics plc [ORTX] managed to generate an average of -$651,185 per employee. Receivables Turnover for the company is 0.17 with a Total Asset Turnover recorded at a value of 0.01.Orchard Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.70 and a Current Ratio set at 5.70.
ORTX Stock EPS
With the latest financial reports released by the company, Orchard Therapeutics plc posted -0.46/share EPS, while the average EPS was predicted by analysts to be reported at -0.44/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -4.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ORTX.
Orchard Therapeutics plc [ORTX] Insider Position Details
There are presently around $454 million, or 67.40% of ORTX stock, in the hands of institutional investors. The top three institutional holders of ORTX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 12,315,213, which is approximately 18.379% of the company’s market cap and around 0.23% of the total institutional ownership; FMR LLC, holding 12,244,590 shares of the stock with an approximate value of $85.83 million in ORTX stocks shares; and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), currently with $48.72 million in ORTX stock with ownership of nearly -4.278% of the company’s market capitalization.
Positions in Orchard Therapeutics plc stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 33 institutional holders increased their position in Orchard Therapeutics plc [NASDAQ:ORTX] by around 4,523,699 shares. Additionally, 41 investors decreased positions by around 7,914,385 shares, while 14 investors held positions by with 52,269,649 shares. The mentioned changes placed institutional holdings at 64,707,733 shares, according to the latest SEC report filing. ORTX stock had 10 new institutional investments in for a total of 69,815 shares, while 16 institutional investors sold positions of 912,216 shares during the same period.